Clinical Trials Browser

Phase 2 × Withdrawn × Ipilimumab × Clear all

NCT06410534 2025-09-11

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT05504642 2023-04-18

CERAD-IMMUNE

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2 Withdrawn

Hemangiosarcoma

NCT04495010 2021-03-19

CheckMate 7UA

Phase 2 Withdrawn

Melanoma

NCT04007588 2020-02-05

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Phase 2 Withdrawn

Melanoma

NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Phase 2 Withdrawn

Basal Cell Nevus Syndrome

NCT01913691 2019-12-17

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Merkel Cell

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

NCT03149159 2018-06-18

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT01530984 2015-10-05

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00357461 2013-05-15

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Phase 2 Withdrawn

Melanoma